Skip to main content
. Author manuscript; available in PMC: 2023 Aug 11.
Published in final edited form as: Antiviral Res. 2022 May 6;203:105330. doi: 10.1016/j.antiviral.2022.105330

Table 1.

Cytotoxicity and antiviral activity of FR and FR-S.

EC50 (SI)
Simultaneous treatment Post-infection treatment
Sample CC50 DENV-2 (Strain 172–06) ZIKV (Strain 2–16) DENV-2 (Strain 172–06) ZIKV (Strain 2–16)
FR >500 NI NI NI NI
FR-S >500 36.50 ± 2.55 (>13.70) 188.70 ± 12.87 (>2.78) NI NI
CEG >100 10.01 ± 0.53 (>9.99) 17.99 ± 0.13 (>5.56) 4.93 ± 0.11 (>20.28) 10.75 ± 0.52 (>9.30)

CC50: 50% cytotoxic concentration for U937-DC-SIGN cells (μg/mL); EC50: 50% effective concentration (μg/mL); Selectivity index values (SI = CC50/EC50) are presented between parenthesis; NI: No inhibitory activity; FR: A. subrufescens polysaccharide; FR-S: Sulfated A. subrufescens polysaccharide; CEG: Celgosivir. Values represent the mean ± SD of three independent experiments.